Objective To explore the clinical value of measuring myoglobin (MYO) for the early diagnosis of ACS and monitoring the effect of thrombolysis. Methods MYO and cTnT, CK、CK-MB were measured. The sensitivity, specificity, positive predicting value and negative predicting value of cTnT and CK-MB at different time points were studied. And the correlation was investigated between the MYO plasma level and the severity of coronary artery lesion according to coronary arteriongraphy. The changes of MYO level with thrombolysis were also observed. Results The concentration of MYO, cTnT, CK, CK-MB in acute myocardial infarction patients were (56?34)?g/L, (0. 05?0. 03 )?g/L,(94?84) U/L,(17?13) U/L respectively, which were higher than that in the healthy controls(P 0. 05). The level of MYO rises to the peak at 5. 26 hours after operating thrombolysis. The peak time was earlier than CK and CK-MB (P

0.05). Conclusion Compound salbutamol sulfate aerosol was able to improve the symptoms of patients with asthma, and the efficacy and safety of this drug are similar to that of Combivent. The results indicated that compound salbutamol sulfate aerosol may be a safe and effective drug in the treatment of asthma.

0.01), no significant differences were observed. The peak SBA of CPZ/SBT and CPZ/TZBT against ESBLs positive K. pneumoniae and E. coli were shown to be slightly stronger than that of CPZ by 2-4 times (P

ObjectiveTo investigate the recent development of Acinetobacter baumannii infection and its drug-resistance.MethodsThe Acinetobacter baumannii infections of inpatients during the year 2001 to June,2005 were analyzed retrospectively. ResultsThe infection of Acinetobacter baumannii increased from 15 strains in 2001 to 68 strains in the first half of 2005.The rate of high drug-resistance strains also raised from 20% to 77%.ConclusionThe incident of infection of Acinetobacter baumannii continuously increased in the past 5 years and became more difficult to treat.

ObjectiveTo investigate the clinical features of chronic lung diseases patients combined with lung fungal infection.MethodsThe data of 216 hospitalized cases with chronic lung diseases were retrospectively analyzed.ResultsThe rate of lung fungal infection of chronic lung diseases patients was 28.1%, and the main pathologic fungal was Candida albicans, about 67.2 %.ConclusionThe chronic lung diseases patient has a higher rate of lung fungal infections compared with other diseases. The measures of preventing, diagnosing and treating lung fungal infection at early stage should be taken.

OBJECTIVE The antimicrobial activity in vitro of mezlocillin／sulbactam(MLBT),piperacillin／tazobactam(Tazocillin,TZXL),mezlocillin(MLXL) and ticarcillin／clavulanic acid(Timentin TMT) against 179 clinical isolates was studied.METHODS MICs were determined by agar dilution method.RESULTS The antimicrobial activity in vitro of MLBT against clinical bacteria was 1-2 times higher than that of MLXL.In vitro,MLBT has higher susceptibility than MLXL against Escherichia coli which have higher rate producing β-lactamase,such as Enterobacter species,Acinetobacter species,et al.,and has higher susceptibility than TMT against Enterobacter and other G- bacillus(P＜0.01).MLBT and TZXL have similar antibacterial spectrum and activity susceptible rate.MIC50 of TZXL was 1-2 times lower than that of the MLBT,but there were no siginficant differences. CONCLUSIONS The antimicrobial spectrum and antimicrobial activity in vitro of MLBT were similar to that of TZXL.

OBJECTIVE Tostuty the antimicrobial activity in vitro of 13 ?-lactams and the combinations of (?-lactams) and(?-lactamase) inhibitors against 84 isolates of Klebsiella pneumoniae and Escherichia coli.METHODS MICs were determined by agar dilution method.RESULTS The antimicrobial activity of combinations of ?-lactams and(?-lactamase) inhibitors was the strongest,and the activity of ?-lactams and qinolones were inferior,and ?-lactams were invalid.CONCLUSIONS In the antimicrobial spectrum and antimicrobial activity the combinations of ?-lactam and ?-lactamase inhibitors were stronger than that of ?-lactam.The use of combinations of ?-lactam and ?-lactamase(inhibitors) may increase the clinical cure rate,and delay the occurrence of resistance.

0.05);the bacterial sensitive rates of amoxicillin/(sulbactam),(amoxicillin)/clavulanate,amoxicillin,ampicillin/sulbactam and cefotaxime were 88.42%,86.78%,57.02%,(86.78%) and 85.95%,respectively;the antibacterial potency of amoxicillin/sulbactam was higher than(amoxicillin)/clavulanate that of from the results of MIC_(90).CONCLUSIONS Amoxicillin/sulbactam has good (bacteriological) efficacy.

ObjectiveTo investigate the diagnosis and correlative factors of suspected severe acute respiratory synd rome (SARS) cases, and finally, complete the diagnosis and treatment.MethodsTo analyze the clinical, laboratory data,chest radiog raph and treatment of 100 suspected SARS cases.ResultsAmong 100 suspected SARS cases,66 were diagnosed as SARS,4 were mycoplasma l pneumonia, 2 were pulmonary tuberculosis,the others were general bacteria pne umonia.Conclusions SARS hasn't characteristic clin ical manifestation.Because there is not a gold diagnosis standard up to now, the disinfection and isolation of suspected SARS cases should be treated as SARS c ases. In order to prevent missed and misdiagnosis, the diagnosis and treatment s hould be synthetically thought.

AIM: To evaluate the safety and tolerance of ibandronate in Chinese healthy volunteers. METHODS: The trial protocol was designed according to the Good Clinical Practice(GCP). After physical examination and laboratory tests were performed, 36 healthy volunteers were divided randomly into 6 dose groups, including 1 mg , 2 mg , 3 mg , 4 mg , 5 mg and 6 mg , with 6 subjects in each group(3 male and 3 female). Clinical symptoms, vital signs, routine blood tests, routine urine tests, hepatic function, renal function, blood electrolytes, electrocardiogram, and electroencephalogram were observed or examined before and after a single intravenous infusion of ibandronate. RESULTS: After single intravenous infusion doses of 1- 6 mg , the vital signs, clinical symptoms and laboratory tests were all in the normal range, but there were some slight ADRs concerned with the drug, such as hypophosphataemia, increased body temperature, perspiring,pain of bone or muscle and hypocalcaemia. But the ADRs were found vanishing in one or two weeks. CONCLUSION: Single intravenous infusion (up to 6 mg ) of domestic ibandronate in 36 chinese healthy volunteers is safe and tolerable.